• 2018-07
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Rodda S Tyldesley S


    [4] Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Ra-diat Oncol Biol Phys 2017;98:286e295.
    [5] Hathout L, Mahmoud O, Barkati M, et al. A phase 2 randomized pi-lot study comparing high-dose rate bracytherapy and low-dose rate brachytherapy as monotherapy in localized prostate cancer. Brachy-therapy 2018;17:S56.
    [6] Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam Y-27632 therapy with external-
    beam radiation therapy alone in node-negative locally advanced can-cer of the prostate. J Clin Oncol 2005;23:1192e1199.
    [7] Hoskin PJ, Colombo A, Henry A, et al. GEC/ESTRO recommenda-tions on high dose rate afterloading brachytherapy for localised pros-tate cancer: An update. Radiother Oncol 2013;107:325e332.
    [8] Bilimoria KY, Stewart AK, Winchester DP, et al. The national cancer data base: A powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683e690.
    [9] Austin PC. The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments. Stat Med 2014;33:1242e1258.
    [10] McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 2013;32:3388e3414.
    [11] Ridgeway G, McCaffrey D, Morral A, et al. Twang: Toolkit for weight-
    ing and analysis of nonequivalent groups 2017. Available at: https:// Accessed September 1, 2018.
    [12] Kishan AU, Shaikh T, Wang P-C, et al. Clinical outcomes for patients with Gleason score 9e10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: A multi-institutional compar-ative analysis. Eur Urol 2017;71:766e773.
    [13] Kishan AU, Cook RR, Ciezki JP, et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer. JAMA 2018;319:896e905.  [14] Shah C, Lanni TB, Ghilezan MI, et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treat-ment of low/intermediate prostate cancer. Brachytherapy 2012;11: 441e445.
    [15] Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012;109:22e29.
    [17] Tward JD, Jarosek S, Chu H, et al. Time course and accumulated risk of severe urinary adverse events after high- versus low-dose-rate prostate brachytherapy with or without external beam radiation ther-apy. Int J Radiat Oncol Biol Phys 2016;95:1443e1453.
    [18] Improving quality of life after prostate brachytherapy: a comparison of HDR and LDR brachytherapy - full text view - Available at: Ac-cessed June 27, 2018.
    [19] Rodda S, Morris WJ, Hamm J, et al. An analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachy-therapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017; 98:581e589. Computer Methods and Programs in Biomedicine 177 (2019) 219–229
    Contents lists available at ScienceDirect
    Computer Methods and Programs in Biomedicine
    journal homepage:
    A comparative study on feature selection for a risk prediction model for colorectal cancer
    Nahúm Cueto-López a, Maria Teresa García-Ordás a, Verónica Dávila-Batista b, Víctor Moreno c,e,d, Nuria Aragonés f, Rocío Alaiz-Rodríguez a,∗